We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

LEICA

Leica Biosystems develops and supplies cancer diagnostics devices and solutions in the areas of histology, digital pa... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
24 Jan 2022 - 27 Jan 2022

Novel Serum Biomarker Investigated for Early Gastric Cancer Diagnosis

By LabMedica International staff writers
Posted on 03 Nov 2021
Print article
Image: The BOND-MAX Fully Automated IHC and ISH Staining System (Photo courtesy of Leica  Microsystems)
Image: The BOND-MAX Fully Automated IHC and ISH Staining System (Photo courtesy of Leica Microsystems)
Gastric cancer (GC) is one of the most common causes of cancer-related death worldwide. More importantly, most reported GC cases are in developing countries. The high mortality of GC is often due to its nonspecific symptoms and delayed diagnosis.

Early detection is key step in the management of patients and survival improvement. Gastric endoscopy is widely used for GC screening. Magnifying endoscopy (ME) with narrow band imaging (ME-NBI) is also an effective tool for real-time endoscopic diagnosis of early gastric cancer (EGC). However, using these tools, identifying subtle lesions or differentiation between inflammation and early intraepithelial neoplasia is still challenging.

Gastroenterologists at the Shanghai General Hospital (Shanghai, China) enrolled a total of 108 patients who presented with GC between July 2016 and June 2018. The subjects included 38 cases of EGC and 70 cases of advanced gastric cancer (AGC). Also included were 28 patients with low-grade intraepithelial neoplasia (LGN, precancerous group), 37 patients with chronic superficial gastritis (CSG) associated with Helicobacter pylori infection (Hpi), 49 patients with other system malignant tumors (OST) and 178 healthy volunteers (healthy control, HC).

Serum samples from 20 patients with EGC and 20 HCs were selected for polypeptide analysis via mass spectrometry. A nanoliter flow HPLC system, EASY-nLC 1000, with a trap column and a C18 column was used in this study and the analysis was performed using the Orbitrap Elite system (Thermo Scientific, Waltham, MA, USA). To confirm the mass spectrometry results, serum samples from 16 patients with EGC, 16 patients with AGC, and 16 HCs were subjected to immunoblotting against inter-alpha-trypsin inhibitor heavy chain 4 (ITIH4).

The tumor tissues of 20 patients with GC and their adjacent normal tissues were embedded, sectioned, and placed in Leica Bond-Max automatic immunohistochemical machine (Leica Microsystems, Berlin, Germany). The expression profiles of ITIH4 in 312 serum samples, including 26 EGC, 48 AGC, 26 LGN, 37 Hpi, 49 OST, and 126 HC serum samples, were determined using enzyme-linked immunosorbent assay (ELISA, R&D Systems, Minneapolis, MN, USA). To determine the expression levels of target molecules in blood, exosomes in serum samples were isolated, identified, and analyzed.

The investigators reported that ITIH4 was identified as a key biomarker in patients with EGC. Its expression level in serum from the EGC group, which showed the highest specificity (94.5%), was significantly higher than those in sera from other GC groups as well as the control. Western blot analysis, immunohistochemical staining, and exosome analysis also confirmed ITIH4 expression in sera from patients with GC, but not in those from healthy individual.

The authors concluded that the serum ITIH4 expression level is a promising biomarker for the early diagnosis of GC. ITIH4 levels in serum samples from patients at the early stage of GC were significantly higher than those in serum samples from patients with GC at the advanced stage or HCs. This finding indicated that serum ITIH4 levels can be a potential biomarker for early stage GC diagnosis. The study was published on October 20, 2021 on the journal Clinica Chimica Acta.

Related Links:
Shanghai General Hospital
Thermo Scientific
Leica Microsystems
R&D Systems


Gold Supplier
INFLUENZA A/B RAPID TEST
COMBO INFLUENZA A+B-CHECK-1
New
Portable Tube Luminometer
Junior LB 9509
New
POC Clinical Chemistry Analyzer
LINX EVO
New
Gold Supplier
SARS-CoV-2 (ORF1a, N, RdRp) Real-Time RT-PCR Test
DiaPlexQ SARS-CoV-2 (ORF1a, N, RdRp)

Print article
IIR Middle East

Channels

Molecular Diagnostics

view channel
Illustration

Point-of-Care Lateral Flow Test Detects Bladder Cancer Using Urine Sample within Minutes

A breakthrough diagnostics platform uses a multiplexed lateral flow assay that detects 10 bladder cancer biomarkers from a urine sample in either laboratory or point-of-care settings. SCIENION (Berlin,... Read more

Hematology

view channel
Image: Bone marrow aspirate from a patient with Acute Myeloid Leukemia: Blasts are the predominant population and have a high nuclear to cytoplasmic ratio and generally lack granules. (Photo courtesy of Professor Peter G. Maslak, MD)

Cord Blood and Matched Related Donor Transplantation Compared in Acute Myeloid Leukemia

The prognosis of primary refractory and relapsed acute myeloid leukemia is poor, with a five-year overall survival of less than 10%. Allogeneic hematopoietic stem cell transplantation (HSCT) is the only... Read more

Industry

view channel
Illustration

Global Immunofluorescence Assay (IFA) Market to Surpass USD 4 Billion by 2028 Due to Growing Burden of Infectious Diseases

The global immunofluorescence assay (IFA) market is expected to reach USD 4.01 billion by 2028, driven by the increasing global healthcare burden of chronic and infectious diseases, rising application... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.